Cedric Hermans/LinkedIn
Aug 13, 2025, 23:32
Cedric Hermans Shares His Vision for the Use of APCC During Emicizumab Prophylaxis
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, recently shared on LinkedIn:
”Personal commentary on the recent important paper by Robert Sidonio et al. on APCC in patients receiving emicizumab prophylaxis published in RPTH.”
Read the full article here.
Article: Cautious use of activated prothrombin complex concentrate in patients receiving emicizumab: new evidence and clinical considerations
Author: Cedric Hermans
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests
-
Aug 26, 2026, 17:46Bruno Pougault: The Hidden Burden of Hemostatic Disorders in Women